Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cooking oil protect the brain in Huntington's?

NCT ID NCT02453061

Disease control Sponsor: Institut National de la Santé Et de la Recherche Médicale, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special oil called triheptanoin can slow brain damage in people with early Huntington's disease. 100 participants took either the oil or a placebo for 6 months, followed by 6 months where everyone got the oil. The main goal was to see if it reduced brain shrinkage and improved energy use in the brain.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Triheptanoin oil
What this could lead to
If it works, this could point toward a treatment that slows brain damage and delays symptoms in Huntington's disease.
What could go wrong
This is a small, early-phase study (Phase 2) with only 100 people. The results may not show clear benefit, and the oil could cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

The number who actually took part.

Started

Jun 2015

Finished

Dec 2019

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Positive genetic test with CAG repeat length ≥39 in HTT gene * At least 18 years of age * Signature of informed consent * Covered by social security * UHDRS score between 5 and 40 * Ability to undergo MRI scanning * BMI between 18 and 30 Exclusion Criteria: * Hypersensitivity to triheptanoin or to one of its excipients * Additional major comorbidities * History of severe head injury * Participation in another therapeutic trial (3 month exclusion period) * For women of childbearing age, the absence of two forms of effective contraception (with the exception of those who are abstinent) * Pregnancy or breastfeeding * Inability to understand information about the protocol * Persons deprived of their liberty by judicial or administrative decision * Adult subject under legal protection or unable to consent * Treatment with tetrabenazine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Huntington disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Huntington disease

Contacts and locations

Locations

  • Department of Neurology

    Leiden, 2300RC, Netherlands

  • Département de Génétique

    Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.